

Registered Company Name	エーザイ 株式会社
English Name	***Redacted***
Previous Name	**Nihon Eizai K. K**
Corporate Number	***Redacted***
Registration Date	06-Dec-1941
Public Register Search	**Positive**
Listed	Yes
Company Type	Private (Joint Stock Company)
Company Status	Active
Country	Japan
Date of Search	29th July 2025
Registered Address	4-6-10, Koishikawa, Bunkyo-ku, Tokyo - 112-8088, Japan
Contact	Tel: +81 3 3817 3700 Website: www.eisai.com
Other addresses	Plant — 1 Kawashimatakehaya-cho, Gifu Pref., Kakamigahara-city - 501-6195, Japan Plant — 22 Sunayama, Ibaraki Pref., Kamisu-city - 314-0255, Japan



	Other Address 5-1-3. Tokodai, Ibaraki Pref., Tsukuba-city - 300-2635, Japan Other Address 6-8-2, Minatojima-Minatomachi, Chuo-ku, Hyogo Pref., KOBE - 650-0047, Japan
Bank	Resona Bank Limited Mizuho Bank Ltd. MUFG Bank Ltd. Resona Bank Limited

Shareholders

Name	Holding (%)
Master Trust Bank of Japan Ltd., trust a/c	19.22
Custody Bank of Japan Ltd., trust a/c	10.74
State Street Bank and Trust Company 505001	6.66
Nippon Life Insurance Company	2.30
State Street Bank West Client – Treaty 505234	1.98
JP Morgan Securities Co. Ltd.	1.57
The Naito Foundation	1.49
JP Morgan Chase Bank 385781	1.31
Resona Bank Limited	1.17
HSBC Hong Kong -Treasury Services A/C Asian Equities	0.90

Comment:

No. of authorized shares : 1 100 000 000
No. of shares outstanding : 291 649 149

Director	Name Ms. Yumiko Miwa Designation Director Nationality Japanese Name Mr. Fumihiko Ike Designation Director Nationality Japanese Name Mr. Haruo Naito




	Designation	Director / Representative Corporate Officer and CEO
	Date / Year of Birth	27-Dec-1947
	Qualification	Keio University / Northwestern University
	Nationality	Japanese
	Comments	Date of Appointment : June-2014
Paid up Capital	JPY 44 986 000 000	
Share Trading Details of the subject at Tokyo Stock Exchange	Market Value as on	25-Jul-2025
	Market Value of share	JPY 4.00
	52 Week High	JPY 6 271.00
	52 Week Low	JPY 3 463.00
Business Operations	The subject is engaged in development, manufacture, sale, import and export of pharmaceutical products. It is one of the largest comprehensive pharmaceutical companies in the global market, with a strong lineup of pharmaceutical products for nervous and digestive systems. Overseas sales represent 60% of total.	
Subsidiary names & details	Eisai Ltd. Eizai Corporation of North America Eizai Ltd. Eisai Europe Ltd Eizai GmbH 48 consolidated subsidiaries and 1 affiliate	
Company History	Dec. 1941: Nihon Eisai K. K. was incorporated. 1955: The corporate name changed to Eisai Co., Ltd. 1961: Its shares were listed on the Tokyo Stock Exchange and Osaka Stock Exchange. 1991:~ Started setting up overseas subsidiaries. Apr. 2007: It acquired Morphotek, Inc. (US). Jan. 2008: It acquired MGI Pharma Inc. (US). 2015: Its 100% stake in Eidia Co., Ltd. was transferred to Sekisui Chemical Co., Ltd. 2016: Its 100% stake in Sannova Co., Ltd. was transferred to Alfresa Holdings Corporation. Apr. 2022: Its shares were listed on the Prime market of the Tokyo Stock Exchange due to reclassification of the stock exchange. May 2025: Acquired Eco Navista Co., Ltd.	

FINANCIAL SUMMARY

NET WORTH

JPY in '000'


Year Ended	Amount	Change
31-Mar-2025	865 968 000	-3.67%
31-Mar-2024	898 975 000	---



TOTAL REVENUE

JPY in '000'


Year Ended	Amount	Change
31-Mar-2025	816 765 000	6.83%
31-Mar-2024	764 553 000	---



PROFIT BEFORE TAX

JPY in '000'


Year Ended	Amount	Change
31-Mar-2025	61 066 000	-1.23%
31-Mar-2024	61 824 000	---



PROFIT AFTER TAX

JPY in '000'

Year Ended	Amount	Change
31-Mar-2025	48 059 000	9.76%
31-Mar-2024	43 784 000	---



BALANCE SHEET

For the Year Ending :	31-Mar-2025	31-Mar-2024

SystemDay
Company Documents Credit Reports Company Formations
www.systemday.com



		(JPY in '000')
Period	(12 months)	(12 months)
Type of Financials	Consolidated	Consolidated
Account Type	Audited	Audited
Source	Public	Public
EQUITY AND LIABILITIES		
Shareholders' Funds	**841 417 000.00**	**875 614 000.00**
- Share Capital	44 986 000.00	44 986 000.00
- Reserves and Surplus	796 431 000.00	830 628 000.00
Non-controlling interest	**24 551 000.00**	**23 361 000.00**
Non-current liabilities	**148 284 000.00**	**190 352 000.00**
- Long-term borrowings	99 832 000.00	134 773 000.00
- Deferred tax liabilities	732 000.00	704 000.00
- Other Long term liabilities	47 720 000.00	54 875 000.00
Current liabilities	**372 295 000.00**	**304 472 000.00**
- Short-term borrowings	87 691 000.00	24 632 000.00
- Trade payables	91 571 000.00	72 249 000.00
- Other current liabilities	193 033 000.00	207 591 000.00
TOTAL	**1 386 547 000.00**	**1 393 799 000.00**
ASSETS		
Non-current assets	**658 888 000.00**	**670 816 000.00**
- Tangible assets	158 088 000.00	164 894 000.00
- Deferred tax assets(net)	101 311 000.00	100 826 000.00
- Other non-current assets	399 489 000.00	405 096 000.00
Current assets	**727 659 000.00**	**722 983 000.00**
- Inventories	215 905 000.00	174 651 000.00
- Trade receivables	220 022 000.00	217 208 000.00
- Cash and cash equivalents	265 561 000.00	304 678 000.00
- Other current assets	25 682 000.00	26 001 000.00
- Other Current Financial Assets	489 000.00	445 000.00



TOTAL	**1 386 547 000.00**	**1 393 799 000.00**

PROFIT & LOSS A/C

For the Year Ending :	**31-Mar-2025**	**31-Mar-2024**
		(JPY in '000')
Revenue		
- Revenue from operations	789 400 000.00	741 751 000.00
- Other income	17 157 000.00	11 998 000.00
- Finance Income	10 208 000.00	10 804 000.00
TOTAL REVENUE	**816 765 000.00**	**764 553 000.00**
Expenses		
- Cost of Sales	168 807 000.00	155 333 000.00
- Selling & Distribution Expenses	407 983 000.00	374 421 000.00
- Research and development expenses	171 633 000.00	169 021 000.00
- Other expenses	3 757 000.00	1 566 000.00
- Finance Cost	3 519 000.00	2 388 000.00
TOTAL EXPENSES	**755 699 000.00**	**702 729 000.00**
Profit (Loss) before tax	**61 066 000.00**	**61 824 000.00**
Tax Expenses		
- Taxes	13 007 000.00	18 040 000.00
Profit (Loss) for the period	**48 059 000.00**	**43 784 000.00**